{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:06:21Z","timestamp":1792058781542,"version":"4.4.0"},"reference-count":187,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejmech.2025.117870","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T11:00:16Z","timestamp":1749898816000},"page":"117870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Dismantling the epigenetic alliance: Emerging strategies to disrupt the PRMT5:MEP50 complex for cancer therapy"],"prefix":"10.1016","volume":"296","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-8933","authenticated-orcid":false,"given":"Faris F.","family":"Aba Alkhayl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117870_bib1","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1007\/s00018-019-03140-2","article-title":"Cellular consequences of arginine methylation","volume":"76","author":"Lorton","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2025.117870_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","article-title":"Protein arginine methylation: from enigmatic functions to therapeutic targeting","volume":"20","author":"Wu","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117870_bib3","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/srep01311","article-title":"Loss of the major type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs","volume":"3","author":"Dhar","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117870_bib4","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","article-title":"The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond, cell","volume":"72","author":"Stopa","year":"2015","journal-title":"Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2025.117870_bib5","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1021\/acs.jmedchem.8b00598","article-title":"Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1134\/S1062360421050064","article-title":"Essential roles of PRMT5-MEP50 complex formation and cancer therapy","volume":"52","author":"Nibona","year":"2021","journal-title":"Russ. J. Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.117870_bib7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41417-021-00327-3","article-title":"PRMT5: a putative oncogene and therapeutic target in prostate cancer","volume":"29","author":"Beketova","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejmech.2025.117870_bib8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bbrc.2006.01.167","article-title":"FBXO11\/PRMT9, a new protein arginine methyltransferase, symmetrically dimethylates arginine residues","volume":"342","author":"Cook","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.117870_bib9","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1038\/ncomms7428","article-title":"PRMT9 is a type II methyltransferase that methylates the splicing factor SAP145","volume":"6","author":"Yang","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117870_bib10","first-page":"17960","article-title":"Crystal structure of the human PRMT5:MEP50 complex","volume":"109","author":"Antonysamy","year":"2012"},{"key":"10.1016\/j.ejmech.2025.117870_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3892\/ijo.2023.5510","article-title":"Research progress on PRMTs involved in epigenetic modification and tumour signalling pathway regulation","volume":"62","author":"Wu","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2025.117870_bib12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1369\/0022155413475452","article-title":"Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer","volume":"61","author":"Bao","year":"2013","journal-title":"J. Histochem. Cytochem."},{"issue":"2021","key":"10.1016\/j.ejmech.2025.117870_bib13","article-title":"Protein arginine methyltransferase 5 functions via interacting proteins","volume":"9","author":"Liang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.117870_bib14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1517\/14728222.2012.688030","article-title":"Protein arginine methyltransferases (PRMTs) as therapeutic targets","volume":"16","author":"Cha","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2025.117870_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.36401\/JIPO-22-1","article-title":"Protein arginine methyltransferase 5 (PRMT5) inhibitors in oncology clinical trials: a review","volume":"5","author":"Feustel","year":"2022","journal-title":"Journal of Immunotherapy and Precision Oncology"},{"key":"10.1016\/j.ejmech.2025.117870_bib16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00280-011-1746-1","article-title":"In Vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues","volume":"69","author":"Haglund","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117870_bib17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41556-025-01610-3","article-title":"PRMT5-mediated arginine methylation stabilizes GPX4 to suppress ferroptosis in cancer","volume":"27","author":"Fan","year":"2025","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117870_bib18","doi-asserted-by":"crossref","first-page":"8407","DOI":"10.1021\/acs.jmedchem.3c00250","article-title":"Targeting arginine methyltransferase PRMT5 for cancer therapy: updated progress and novel strategies","volume":"66","author":"Zheng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib19","doi-asserted-by":"crossref","first-page":"13793","DOI":"10.1021\/acs.jmedchem.2c01000","article-title":"Discovery and biological characterization of PRMT5:MEP50 protein\u2013protein interaction inhibitors","volume":"65","author":"Asberry","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.tibs.2011.09.001","article-title":"Versatility of PRMT5-induced methylation in growth control and development","volume":"36","author":"Karkhanis","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2025.117870_bib21","doi-asserted-by":"crossref","first-page":"7842","DOI":"10.3390\/ijms24097842","article-title":"Targeting protein\u2013protein interfaces with peptides: the contribution of chemical combinatorial peptide library approaches","volume":"24","author":"Monti","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117870_bib22","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/s42003-022-03991-9","article-title":"Cryo-EM structure-based selection of computed ligand poses enables design of MTA-Synergic PRMT5 inhibitors of better potency","volume":"5","author":"Zhou","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2025.117870_bib23","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1021\/acs.biochem.5b01129","article-title":"Protein methyltransferases: a distinct, diverse, and dynamic family of enzymes","volume":"55","author":"Boriack-Sjodin","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.117870_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/e6b5348e-9052-4a3b-8f06-90d01dc88fc2","article-title":"Structure of the arginine methyltransferase PRMT5-MEP50 reveals a mechanism for substrate specificity","volume":"8","author":"Ho","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117870_bib25","series-title":"Protein Arginine Methyltransferases: Catalytic Mechanisms and Crosstalk in Epigenetics","author":"Jain","year":"2018"},{"key":"10.1016\/j.ejmech.2025.117870_bib26","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.1074\/jbc.M115.636894","article-title":"Histone H2A and H4 N-terminal tails are positioned by the MEP50 WD repeat protein for efficient methylation by the PRMT5 arginine methyltransferase","volume":"290","author":"Burgos","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004049","article-title":"The roles of post-translational modifications in the context of protein interaction networks","volume":"11","author":"Duan","year":"2015","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ejmech.2025.117870_bib28","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.3390\/ijms25052842","article-title":"Inhibition of PRMT5\/MEP50 arginine methyltransferase activity causes cancer vulnerability in NDRG2low adult T-Cell leukemia\/lymphoma","volume":"25","author":"Ichikawa","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117870_bib29","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3390\/life11101074","article-title":"The structure and functions of PRMT5 in human diseases","volume":"11","author":"Motolani","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.ejmech.2025.117870_bib30","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.3390\/ijms25073958","article-title":"Protein arginine methyltransferases in pancreatic ductal adenocarcinoma: new molecular targets for therapy","volume":"25","author":"Bhandari","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117870_bib31","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.1021\/acs.jmedchem.4c03101","article-title":"From DNA-encoded library screening to AM-9747: an MTA-cooperative PRMT5 inhibitor with potent oral in Vivo efficacy","volume":"68","author":"Sarvary","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib32","series-title":"Neuroepigenetics Mechanisms in Health and Disease","first-page":"1","article-title":"Basic epigenetic mechanisms","author":"Davie","year":"2025"},{"key":"10.1016\/j.ejmech.2025.117870_bib33","series-title":"Understanding the Epigenetic Role of PRMT1\/H4R3me2a in Cancer Cells","author":"Narayanan Sudhakar","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117870_bib34","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/molecules29030728","article-title":"Natural compounds in non-melanoma skin cancer: prevention and treatment","volume":"29","author":"Kowalski","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117870_bib35","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s41467-024-46495-2","article-title":"PRMT5 is an actionable therapeutic target in CDK4\/6 inhibitor-resistant ER+\/RB-deficient breast cancer","volume":"15","author":"Lin","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117870_bib36","series-title":"Productive Mrna Chromatin Escape Is Promoted by PRMT5 Methylation of SNRPB","author":"DeAngelo","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117870_bib37","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/cbic.202100079","article-title":"Biochemical investigation of the interaction of pICln, RioK1 and COPR5 with the PRMT5\u2013MEP50 complex","volume":"22","author":"Krzyzanowski","year":"2021","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.117870_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2021.07.019","article-title":"Molecular basis for substrate recruitment to the PRMT5 methylosome","volume":"81","author":"Mulvaney","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.117870_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adm9589","article-title":"A PRMT5-ZNF326 axis mediates innate immune activation upon replication stress","volume":"10","author":"Hoang","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2025.117870_bib40","series-title":"Pre\u2010Mrna Splicing Modulation, RNA as a Drug Target: the next Frontier for Medicinal Chemistry","first-page":"151","author":"Barraza","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117870_bib41","series-title":"Targeting PRMT5 Impairs Cancer Proliferation Through Splicing but Promotes State Shifts that Enable Resistance and Disease Progression","author":"Fowler","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117870_bib42","series-title":"Universit\u00e9 Paris Sciences Et Lettres Universit\u00e9 Libanaise","article-title":"Investigating PRMT5 functions in triple-negative breast cancers Etude du r\u00f4le de PRMT5 dans les cancers du sein triple-n\u00e9gatifs","author":"Dakroub","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117870_bib43","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/JID.2015.400","article-title":"MEP50\/PRMT5 reduces gene expression by histone arginine methylation and this is reversed by PKC\u03b4\/p38\u03b4 signaling","volume":"136","author":"Saha","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2025.117870_bib44","series-title":"In Vivo Shrna Screen Reveals PRMT5 as a Key Regulator in Glioblastoma","author":"Stanciu","year":"2017"},{"key":"10.1016\/j.ejmech.2025.117870_bib45","series-title":"PRMT5 Is an Essential Survival Factor for Ground State Pluripotency and Primordial Germ Cells: from Primordial Germ Cell Differentiation in Vitro to Mammalian Germline in Vivo","author":"Li","year":"2014"},{"key":"10.1016\/j.ejmech.2025.117870_bib46","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.3390\/cancers13205136","article-title":"PRMT5: an emerging target for pancreatic adenocarcinoma","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2025.119923","article-title":"Aberrant miRNA expression and protein arginine methyltransferase 5 (PRMT5) in cancer: a review","volume":"1872","author":"Sif","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ejmech.2025.117870_bib48","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1016\/j.molcel.2021.09.011","article-title":"Cellular pathways influenced by protein arginine methylation: implications for cancer","volume":"81","author":"Xu","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.117870_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1455572","article-title":"Emerging roles of cancer-associated histone mutations in genomic instabilities","volume":"12","author":"Yadav","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.117870_bib50","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.3390\/cancers15245855","article-title":"PRMT5 as a potential therapeutic target in MYC-amplified medulloblastoma","volume":"15","author":"Kumar","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"key":"10.1016\/j.ejmech.2025.117870_bib52","article-title":"Transcriptional regulation by PRMT5","author":"DeAngelo","year":"2024","journal-title":"Albert Einstein College of Medicine"},{"key":"10.1016\/j.ejmech.2025.117870_bib53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/13543776.2023.2201436","article-title":"A patent review of PRMT5 inhibitors to treat cancer (2018 - present)","volume":"33","author":"Gao","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2025.117870_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107859","article-title":"Medicinal chemistry insights into PRMT5 inhibitors","volume":"153","author":"Jiao","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib55","doi-asserted-by":"crossref","first-page":"8854","DOI":"10.3390\/ijms25168854","article-title":"Role of PRMT1 and PRMT5 in breast cancer","volume":"25","author":"Martinez","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117870_bib56","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1101\/gad.219899.113","article-title":"Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery","volume":"27","author":"Bezzi","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2025.117870_bib57","first-page":"17990","article-title":"Regulation of PRMT5\u2013MDM4 axis is critical in the response to CDK4\/6 inhibitors in melanoma","volume":"116","author":"AbuHammad","year":"2019"},{"key":"10.1016\/j.ejmech.2025.117870_bib58","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.3390\/cancers14143426","article-title":"ZEB2\/TWIST1\/PRMT5\/NuRD multicomplex contributes to the epigenetic regulation of EMT and metastasis in colorectal carcinoma","volume":"14","author":"Zheng","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib59","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.3390\/cells10123435","article-title":"Aspects of the epigenetic regulation of EMT related to cancer metastasis","volume":"10","author":"Nowak","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.117870_bib60","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/genes14030678","article-title":"The role of PRMT5 in immuno-oncology","volume":"14","author":"Abe","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2025.117870_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114842","article-title":"Medicinal chemistry strategies targeting PRMT5 for cancer therapy","volume":"244","author":"Fu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib62","article-title":"Consequences of post-translational modifications on chromatin associated proteins","author":"Lorton","year":"2021","journal-title":"Albert Einstein College of Medicine"},{"key":"10.1016\/j.ejmech.2025.117870_bib63","series-title":"TU Dortmund Dortmund","article-title":"Targeting PRMT5 protein-protein interactions with peptidic modulators","author":"Krzyzanowski","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117870_bib64","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.7150\/ijbs.89498","article-title":"Protein arginine methylation in viral infection and antiviral immunity","volume":"19","author":"Zheng","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2025.117870_bib65","series-title":"PRMT5 Upregulation and its Oncogenic Role in Diffuse Large B Cell Lymphoma","author":"Zhu","year":"2019"},{"key":"10.1016\/j.ejmech.2025.117870_bib66","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41420-023-01299-z","article-title":"PRMT5-mediated regulatory arginine methylation of RIPK3","volume":"9","author":"Chauhan","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2025.117870_bib67","series-title":"Structural Investigation into RioK1 for Cancer Therapeutics","author":"Hunter","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117870_bib68","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1074\/jbc.M110.148486","article-title":"RioK1, a new interactor of protein arginine methyltransferase 5 (PRMT5), competes with pICln for binding and modulates PRMT5 complex composition and substrate specificity \u2217","volume":"286","author":"Guderian","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib69","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41420-023-01704-7","article-title":"The RioK1 network determines p53 activity at multiple levels","volume":"9","author":"Damizia","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2025.117870_bib70","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00412-017-0637-6","article-title":"UsnRNP biogenesis: mechanisms and regulation","volume":"126","author":"Gruss","year":"2017","journal-title":"Chromosoma"},{"key":"10.1016\/j.ejmech.2025.117870_bib71","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1038\/s41598-018-28002-y","article-title":"Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing","volume":"8","author":"Gerhart","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117870_bib72","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1021\/acs.jmedchem.4c02106","article-title":"Small-molecule modulators targeting coactivator-associated arginine methyltransferase 1 (CARM1) as therapeutic agents for cancer treatment: current medicinal chemistry insights and emerging opportunities","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib73","series-title":"MYCN-driven Neuroblastoma","article-title":"Exploring the oncogenic role of the splicing associated protein, SNRPD3","author":"Salib","year":"2021"},{"key":"10.1016\/j.ejmech.2025.117870_bib74","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","article-title":"AMG 193, a clinical stage MTA-Cooperative PRMT5 inhibitor, drives antitumor activity preclinically and in patients with MTAP-Deleted cancers","volume":"15","author":"Belmontes","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.117870_bib75","doi-asserted-by":"crossref","first-page":"39653","DOI":"10.1039\/D4RA05497K","article-title":"A review of the known MTA-Cooperative PRMT5 inhibitors","volume":"14","author":"Hu","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.117870_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.35389","article-title":"Therapeutic targeting of chromatin alterations in leukemia and solid tumors","author":"Perner","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117870_bib77","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41589-022-00997-6","article-title":"Targeting allosteric regulation of cancer metabolism","volume":"18","author":"Kremer","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117870_bib78","series-title":"Intrafamily Heterooligomerization of the N-Terminal Methyltransferase METTl11A","author":"Hobble","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117870_bib79","series-title":"Customized Approaches for Inhibition and Degradation of Drug Targets","author":"Li","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117870_bib80","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400639","article-title":"Current approaches and strategies applied in first\u2010In\u2010Class drug discovery","volume":"20","author":"Mohammed","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117870_bib81","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s11030-022-10557-8","article-title":"Virtual screening for potential discoidin domain receptor 1 (DDR1) inhibitors based on structural assessment","volume":"27","author":"Xie","year":"2023","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2025.117870_bib82","series-title":"Epigenetic Drug Discovery","article-title":"Recent developments in the structural mechanism of protein methyltransferase inhibition","author":"Leung","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117870_bib83","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/13543776.2022.2163162","article-title":"An updated patent review of protein arginine N-methyltransferase inhibitors (2019\u20132022)","volume":"32","author":"Dong","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2025.117870_bib84","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1039\/D1CB00101A","article-title":"Targeting protein\u2013protein interactions in the DNA damage response pathways for cancer chemotherapy","volume":"2","author":"McPherson","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117870_bib85","series-title":"Identifying Targets of Sulforaphane in Mesothelioma","author":"Ezeka","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117870_bib86","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/cancers16020244","article-title":"Harnessing sulforaphane potential as a chemosensitizing agent: a comprehensive review","volume":"16","author":"Sailo","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib87","series-title":"A Study of the Snd1\/Prmt5 Axis in Liver Cancer by Genetic Mouse Models","author":"Wright","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117870_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128653","article-title":"Targeting epigenetic modulators using PROTAC degraders: current status and future perspective","volume":"63","author":"Webb","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.117870_bib89","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/mc.23479","article-title":"Sulforaphane inhibits CD44v6\/YAP1\/TEAD signaling to suppress the cancer phenotype","volume":"62","author":"Chen","year":"2023","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ejmech.2025.117870_bib90","series-title":"The Role of Isothiocyanates as Epigenetic Modulators in Malignant Melanoma","author":"Mitsiogianni","year":"2020"},{"key":"10.1016\/j.ejmech.2025.117870_bib91","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/carcin\/bgx044","article-title":"Sulforaphane suppresses PRMT5\/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation","volume":"38","author":"Saha","year":"2017","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejmech.2025.117870_bib92","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1021\/acs.jmedchem.1c01208","article-title":"Fascinating transformation of SAM-competitive protein methyltransferase inhibitors from nucleoside analogues to non-nucleoside analogues","volume":"65","author":"Talukdar","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115605","article-title":"Clinical efficiency of epigenetic drugs therapy in bone malignancies","volume":"143","author":"de Nigris","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.ejmech.2025.117870_bib94","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3390\/genes15091231","article-title":"Menin in cancer","volume":"15","author":"Majer","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2025.117870_bib95","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/mc.23301","article-title":"Sulforaphane inhibits PRMT5 and MEP50 function to suppress the mesothelioma cancer cell phenotype","volume":"60","author":"Ezeka","year":"2021","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ejmech.2025.117870_bib96","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/epigenomes5010002","article-title":"The role of the PRMT5\u2013SND1 axis in hepatocellular carcinoma","volume":"5","author":"Wright","year":"2021","journal-title":"Epigenomes"},{"key":"10.1016\/j.ejmech.2025.117870_bib97","doi-asserted-by":"crossref","first-page":"105","DOI":"10.17219\/pim\/189406","article-title":"Efficacy of sulforaphane in skin cancer animal models: a systematic review","volume":"54","author":"MasoomA","year":"2024","journal-title":"Polim. Med."},{"key":"10.1016\/j.ejmech.2025.117870_bib98","series-title":"The Antioxidant Sulforaphane (SFN) Elicits It's Cytotoxicity by Inactivating the Promyelocytic Leukemia Protein (PML)","author":"Alhazmi","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117870_bib99","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/ph16081095","article-title":"Histone modification of colorectal cancer by natural products","volume":"16","author":"Geng","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.117870_bib100","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/antiox13091092","article-title":"A review of recent curcumin analogues and their antioxidant, anti-inflammatory, and anticancer activities","volume":"13","author":"Kaur","year":"2024","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejmech.2025.117870_bib101","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/biology13040216","article-title":"PRMT5 mediated HIF1\u03b1 signaling and ras-related nuclear protein as promising biomarker in hepatocellular carcinoma","volume":"13","author":"Abumustafa","year":"2024","journal-title":"Biology"},{"key":"10.1016\/j.ejmech.2025.117870_bib102","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1111\/febs.17037","article-title":"Alpha\u2010synuclein promotes PRMT5\u2010mediated H4R3me2s histone methylation by interacting with the BAF complex","volume":"291","author":"Nakamura","year":"2024","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2025.117870_bib103","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.7150\/thno.53023","article-title":"PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression","volume":"11","author":"Yang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2025.117870_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117847","article-title":"Recent contributions of pyridazine as a privileged scaffold of anticancer agents in medicinal chemistry: an updated review","volume":"111","author":"Liu","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116526","article-title":"Small molecules that regulate the N6-methyladenosine RNA modification as potential anti-cancer agents","volume":"274","author":"Harrahill","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib106","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11010-018-3471-0","article-title":"Curcumin ameliorates PRMT5-MEP50 arginine methyltransferase expression by decreasing the Sp1 and NF-YA transcription factors in the A549 and MCF-7 cells","volume":"455","author":"Chatterjee","year":"2019","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2025.117870_bib107","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.3390\/cancers15225478","article-title":"Anticarcinogenic potency of EF24: an overview of its pharmacokinetics, efficacy, mechanism of action, and nanoformulation for drug delivery","volume":"15","author":"Sazdova","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib108","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/cancers17030484","article-title":"Curcumin and its derivatives in hepatology: therapeutic potential and advances in nanoparticle formulations","volume":"17","author":"Karatayli","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib109","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175023","article-title":"PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression","volume":"134","author":"Yan","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.117870_bib110","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s42003-024-06290-7","article-title":"PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth","volume":"7","author":"Abe","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2025.117870_bib111","doi-asserted-by":"crossref","first-page":"18993","DOI":"10.1021\/acs.jmedchem.4c01472","article-title":"Structure-guided discovery of selective USP7 inhibitors with in Vivo activity","volume":"67","author":"Vasas","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib112","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2304071120","article-title":"Structural insights into the interaction of three Y-shaped ligands with PI3K\u03b1","volume":"120","author":"Zhou","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2025.117870_bib113","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217248","article-title":"Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ER\u03b1+ breast cancer","volume":"15","author":"Poulard","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2025.117870_bib114","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1021\/acs.chemrev.4c00332","article-title":"Therapeutic reprogramming toward regenerative medicine","volume":"125","author":"Ding","year":"2025","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2025.117870_bib115","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1021\/acs.jnatprod.7b00112","article-title":"Natural products discovered in a high-throughput screen identified as inhibitors of RGS17 and as cytostatic and cytotoxic agents for lung and prostate cancer cell lines","volume":"80","author":"Bodle","year":"2017","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2025.117870_bib116","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-024-02036-3","article-title":"New insights into protein\u2013protein interaction modulators in drug discovery and therapeutic advance","volume":"9","author":"Nada","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.117870_bib117","series-title":"Spatially Variable Genes in Cancer: Development, Progression, and Treatment Response","first-page":"447","article-title":"Small molecule inhibitors","author":"Selvakumar","year":"2025"},{"key":"10.1016\/j.ejmech.2025.117870_bib118","series-title":"Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention","first-page":"35","article-title":"Bioactive compounds in cancer therapy and chemoprevention","author":"Keerthana","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117870_bib119","series-title":"Pharmacological Targeting of Chromosome 9p21 Deletion for Effective Therapy of Malignant Pleural Mesothelioma","author":"Nusrat","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117870_bib120","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1038\/sj.onc.1203942","article-title":"A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer","volume":"19","author":"Schmid","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117870_bib121","doi-asserted-by":"crossref","first-page":"14380","DOI":"10.18632\/oncotarget.7486","article-title":"The essential role of methylthioadenosine phosphorylase in prostate cancer","volume":"7","author":"Bistulfi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.117870_bib122","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1039\/D3CB00018D","article-title":"Chemical probes and methods for the study of protein arginine methylation","volume":"4","author":"Brown","year":"2023","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117870_bib123","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1021\/acs.jmedchem.4c01998","article-title":"MTA-cooperative PRMT5 inhibitors: mechanism switching through structure-based design","volume":"68","author":"Cottrell","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib124","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1021\/acs.jmedchem.4c02732","article-title":"Discovery of potent, highly selective, and orally bioavailable MTA cooperative PRMT5 inhibitors with robust in Vivo antitumor activity","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102961","article-title":"A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations","volume":"9","author":"Rodon","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejmech.2025.117870_bib126","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009600","article-title":"MTA-Cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-Loss tumors","volume":"12","author":"Chen","year":"2024","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.ejmech.2025.117870_bib127","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/13543776.2023.2201436","article-title":"A patent review of PRMT5 inhibitors to treat cancer (2018-present)","volume":"33","author":"Gao","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2025.117870_bib128","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.3390\/cancers14235739","article-title":"NDRG1 in cancer: a suppressor, promoter, or both?","volume":"14","author":"Joshi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s43046-024-00240-4","article-title":"Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy","volume":"36","author":"Norollahi","year":"2024","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2025.117870_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117145","article-title":"Protein arginine methyltransferase 5 confers the resistance of triple-negative breast cancer to nanoparticle albumin-bound paclitaxel by enhancing autophagy through the dimethylation of ULK1","volume":"493","author":"Kong","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117870_bib131","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.3390\/cancers16081500","article-title":"Heat shock proteins, a double-edged sword: significance in cancer progression, chemotherapy resistance and novel therapeutic perspectives","volume":"16","author":"Kunachowicz","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib132","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.2174\/1568026623666230712120527","article-title":"Research progress on small-molecule inhibitors of protein arginine methyltransferase 5 (PRMT5) for treating cancer","volume":"23","author":"Guo","year":"2023","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216990","article-title":"Nanoparticle-mediated metronomic chemotherapy in cancer: a paradigm of precision and persistence","volume":"594","author":"Kirti","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.117870_bib134","series-title":"The Role of WDR77 in Cancer: More than a PRMT5 Interactor","author":"Silverman","year":"2025"},{"key":"10.1016\/j.ejmech.2025.117870_bib135","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3390\/cells11091403","article-title":"Targeting epigenetic modifiers of tumor plasticity and cancer stem cell behavior","volume":"11","author":"Kumar","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.117870_bib136","series-title":"Investigating Epigenetic Therapies and Combinations for the Treatment of Cancers","author":"O'Brien","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117870_bib137","doi-asserted-by":"crossref","DOI":"10.1007\/s11010-024-05199-3","article-title":"Metabolic reprogramming and signaling adaptations in anoikis resistance: mechanisms and therapeutic targets","author":"He","year":"2025","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2025.117870_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1441081","article-title":"Multidimensional analysis of tumor stem cells: from biological properties, metabolic adaptations to immune escape mechanisms","volume":"12","author":"Han","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.117870_bib139","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3390\/cancers14040970","article-title":"Intrinsic and extrinsic factors impacting cancer stemness and tumor progression","volume":"14","author":"Ponomarev","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib140","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s10020-024-00842-7","article-title":"Potential mechanisms of cancer prevention and treatment by sulforaphane, a natural small molecule compound of plant-derived","volume":"30","author":"Liu","year":"2024","journal-title":"Molecular Medicine"},{"key":"10.1016\/j.ejmech.2025.117870_bib141","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4236\/jct.2023.1411036","article-title":"Prostate cancer, castration-resistant prostate cancer (CRPC), Radium-223 dichloride injection for bone metastasized prostate cancer","volume":"14","author":"Achchillage","year":"2023","journal-title":"J. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.117870_bib142","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/acsomega.4c08661","article-title":"Discovery of PRMT5 N-Terminal TIM barrel ligands from machine-learning-based virtual screening","volume":"10","author":"Shen","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.117870_bib143","article-title":"Recent advances in prostate cancer: WNT signaling, chromatin regulation, and transcriptional coregulators","volume":"25","author":"Takahashi","year":"2023","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.ejmech.2025.117870_bib144","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.3390\/cancers14194766","article-title":"Expression, localization and prognosis association of MEP50 in breast cancer","volume":"14","author":"Suresh","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib145","doi-asserted-by":"crossref","first-page":"36705","DOI":"10.18632\/oncotarget.26404","article-title":"Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer","volume":"9","author":"Shailesh","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.117870_bib146","article-title":"Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment","author":"Zhang","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2025.117870_bib147","doi-asserted-by":"crossref","DOI":"10.1089\/ars.2023.0465","article-title":"Epigenetic control of redox pathways in cancer progression","author":"Shah","year":"2025","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejmech.2025.117870_bib148","series-title":"Role of PRMT5 in ULK1-Mediated Autophagy and Breast Cancer Therapy","author":"Brobbey","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117870_bib149","series-title":"Role of CARM1 (PRMT4) in High Grade Serous Ovarian Cancer Metabolism and Function of PRMT5 in ARID1A-deficient Endometrial Cancer Invasion","author":"Lombardi","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117870_bib150","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41598-023-48652-x","article-title":"PRMT5 inhibition shows In Vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival In Vivo","volume":"14","author":"Brown","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117870_bib151","first-page":"12","article-title":"The epigenetic mechanisms involved in the treatment resistance of glioblastoma","volume":"8","author":"Shahani","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.ejmech.2025.117870_bib152","series-title":"CX3CR1 Phenotypic Plasticity in Prostate Cancer Metastasis","author":"Zhang","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117870_bib153","first-page":"371","article-title":"Cancer dependencies: PRMT5 and MAT2A in MTAP\/p16-deleted cancers","volume":"5","author":"Marjon","year":"2021","journal-title":"Annu. Rev. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117870_bib154","series-title":"Resistance to PRMT5 Targeted Therapy in MCL and Proposed Investigation of Chemotherapeutic Resistance in Canine DLBCL","author":"Long","year":"2023"},{"key":"10.1016\/j.ejmech.2025.117870_bib155","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/onc.2016.205","article-title":"A TGF\u03b2-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression","volume":"36","author":"Chen","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117870_bib156","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.509","article-title":"Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance","volume":"5","author":"Dahan","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.117870_bib157","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.3390\/cancers13205136","article-title":"PRMT5: an emerging target for pancreatic adenocarcinoma","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib158","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1264785","article-title":"The potential and challenges of targeting MTAP-Negative cancers beyond synthetic lethality","volume":"13","author":"Bray","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.117870_bib159","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/biomedicines12010201","article-title":"Anticancer drug discovery based on natural products: from computational approaches to clinical studies","volume":"12","author":"Chunarkar-Patil","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2025.117870_bib160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13046-024-03270-x","article-title":"PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands","volume":"44","author":"Mishra","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117870_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115484","article-title":"PRMT5-mediated methylation of METTL3 promotes cisplatin resistance in ovarian cancer by facilitating DNA repair mechanisms","volume":"44","author":"Xia","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.117870_bib162","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13148-025-01841-z","article-title":"Advances in epigenetic treatment of adult T-cell leukemia\/lymphoma: a comprehensive review","volume":"17","author":"Letafati","year":"2025","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2025.117870_bib163","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.3390\/cancers16223789","article-title":"PRMT5\/WDR77 enhances the proliferation of squamous cell carcinoma via the \u0394Np63\u03b1-p21 axis","volume":"16","author":"Liang","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib164","doi-asserted-by":"crossref","first-page":"7225","DOI":"10.1093\/nar\/gkae319","article-title":"PRMT5-mediated arginine methylation of FXR1 is essential for RNA binding in cancer cells","volume":"52","author":"Vijayakumar","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.117870_bib165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117870_bib166","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/gutjnl-2024-332998","article-title":"Identification of PRMT5 as a therapeutic target in cholangiocarcinoma","volume":"74","author":"Elurbide","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2025.117870_bib167","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41388-024-03264-1","article-title":"PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells","volume":"44","author":"Gillespie","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117870_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110582","article-title":"PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade","volume":"38","author":"Srour","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.117870_bib169","first-page":"9","article-title":"Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches","volume":"8","author":"Khorasanchi","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.ejmech.2025.117870_bib170","article-title":"Androgen receptor signalling pathway and possible therapeutic targets","volume":"39","author":"Altun","year":"2025","journal-title":"Prostate Cancer, DEU T\u0131p Fak\u00fcltesi Dergisi-Developments and Experiments in Health and Medicine"},{"key":"10.1016\/j.ejmech.2025.117870_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107609","article-title":"Deciphering molecular mechanisms underlying the inhibition of \u03b2-glucuronidase by xanthones from Centaurium spicatum","volume":"150","author":"Kamel","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib172","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3390\/molecules29071433","article-title":"Deciphering the molecular mechanisms of reactive metabolite formation in the mechanism-based inactivation of cytochrome p450 1B1 by 8-Methoxypsoralen and assessing the driving effect of phe268","volume":"29","author":"Kamel","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117870_bib173","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252313121","article-title":"Overcoming challenges in small-molecule drug bioavailability: a review of key factors and approaches","volume":"25","author":"Wu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117870_bib174","doi-asserted-by":"crossref","unstructured":"U. John, N.J. Dar, S.A. Bhat, Small molecules: an emerging therapeutic frontier, in: Small Molecules in Neurodegeneration, CRC Press, pp. 20-36.","DOI":"10.1201\/9781003520610-2"},{"key":"10.1016\/j.ejmech.2025.117870_bib175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.55705\/cmbr.2025.456494.1246","article-title":"Recent breakthroughs in drug delivery systems for targeted cancer therapy: an overview, cellular","volume":"5","author":"Reddy","year":"2025","journal-title":"Molecular and Biomedical Reports"},{"key":"10.1016\/j.ejmech.2025.117870_bib176","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1016\/j.apsb.2024.05.010","article-title":"Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy","volume":"14","author":"Peng","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117870_bib177","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/cancers17060958","article-title":"Opportunities and challenges in antibody\u2013drug conjugates for cancer therapy: a new era for cancer treatment","volume":"17","author":"Buyukgolcigezli","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116887","article-title":"Overview of PRMT1 modulators: inhibitors and degraders","volume":"279","author":"Wu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117870_bib179","article-title":"Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance","volume":"15","author":"Wu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.117870_bib180","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3390\/cells13231994","article-title":"Effect of small-molecule natural compounds on pathologic mast cell\/basophil activation in allergic diseases","volume":"13","author":"Werner","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.117870_bib181","series-title":"Spatially Variable Genes in Cancer: Development, Progression, and Treatment Response: Development, Progression, and Treatment Response","first-page":"447","article-title":"Small molecule inhibitors","author":"Bhattacharya","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117870_bib182","series-title":"Protein Arginine Methyltransferase 5 (PRMT5) Is an Essential Regulator of the Cellular Response to Ionizing Radiation and a Therapeutic Target to Enhance Radiation Therapy for Prostate Cancer Treatment","author":"Owens","year":"2020"},{"key":"10.1016\/j.ejmech.2025.117870_bib183","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.3390\/cancers16132478","article-title":"Emerging therapeutic strategies to overcome drug resistance in cancer cells","volume":"16","author":"Garg","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117870_bib184","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1455415","article-title":"Therapeutic targeting potential of the protein lysine and arginine methyltransferases to reverse cancer chemoresistance","volume":"11","author":"Micallef","year":"2024","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2025.117870_bib185","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-Cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-Deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.117870_bib186","series-title":"Mechanisms and Consequences of Resistance to PRMT5 Inhibition","author":"Mueller","year":"2021"},{"key":"10.1016\/j.ejmech.2025.117870_bib187","series-title":"Weill Medical College of","article-title":"Arginine methylation of the RNA-binding protein MUSASHI2 regulates normal and malignant blood fate","author":"Evans","year":"2024"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500635X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342500635X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T08:42:21Z","timestamp":1754988141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342500635X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":187,"alternative-id":["S022352342500635X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117870","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dismantling the epigenetic alliance: Emerging strategies to disrupt the PRMT5:MEP50 complex for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117870"}}